Head-To-Head Survey: Rhythm Pharmaceuticals (RYTM) and Its Rivals

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Rhythm Pharmaceuticals to related businesses based on the strength of its profitability, risk, earnings, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Rhythm Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals 1 3 18 0 2.77
Rhythm Pharmaceuticals Competitors 9941 15328 45742 1605 2.54

Rhythm Pharmaceuticals currently has a consensus target price of $142.00, suggesting a potential upside of 21.77%. As a group, “Biotechnology” companies have a potential upside of 134.36%. Given Rhythm Pharmaceuticals’ peers higher probable upside, analysts plainly believe Rhythm Pharmaceuticals has less favorable growth aspects than its peers.

Volatility and Risk

Rhythm Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals’ peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Insider & Institutional Ownership

47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Rhythm Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals -69.03% -171.16% -43.00%
Rhythm Pharmaceuticals Competitors -12,224.75% -204.85% -31.52%

Valuation and Earnings

This table compares Rhythm Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Rhythm Pharmaceuticals $189.76 million -$196.54 million -40.21
Rhythm Pharmaceuticals Competitors $688.58 million $7.69 million -18.30

Rhythm Pharmaceuticals’ peers have higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Rhythm Pharmaceuticals peers beat Rhythm Pharmaceuticals on 7 of the 12 factors compared.

About Rhythm Pharmaceuticals

(Get Free Report)

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.